The Pharmacology of Bimatoprost (Lumigan™)

References 

1. Bill A. Further studies on the influence of the IOP on aqueous humor dynamics in cynomolgus monkeys. Invest Opththalmol. 1967;6:364–372
2. Brandt JD, VanDenburgh AM, Whitcup SM, et al: The Bimatoprost Study Group 1. Comparison of once and twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (in press)
3. Brubaker RF, Schoeff EO, Nau CB, et al.  Effects of bimatoprost, a new ocular hypotensive agent, on aqueous humor dynamics. Am J Ophthalmol. 2001;131:19–24
   • Abstract
   • Full Text
   • Full-Text PDF (217 KB)
   • CrossRef
4. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiated by endogenous cannabinoids. Nature. 1988;394:277–281
   • MEDLINE
   • CrossRef
5. Cravatt BF, Prospero-Garcia O, Siuzdak G, et al.  Chemical characterization of a family of brain lipids that induce sleep. Science. 1995;268:1506–1509
   • MEDLINE
6. Devane WA, Hanus L, Breuer A, et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949
   • MEDLINE
7. Di Marzo V. “Endocannabinoids” and other fatty acid derivatives with cannabimimetic properties (biochemistry and possible physiological relevance). Biochim Biophys Acta. 1998;1392:153–175
   • MEDLINE
8. Dirks M, Dubiner H, Cooke D, et al.  Efficacy and safety of the ocular hypotensive lipid AGN 192024 in patients with elavated IOP (a 30-day comparison with latanoprost). Invest Ophthalmol Vis Sci. 2000;41:S514;[abstract]
9. Joyner WL, Gilmore JP. Tissues grafted into the cheek pouch of the hamster. In:  Baker CH,  Nastuk WL editor. Microcirculatory Technology. Physical Techniques in Biology and Medicine. Academic Press: London; 1986;p. 3–17
10. Krauss AH-P, Woodward DF, Protzman CE, et al: Evidence for a novel receptor in the cat iris that recognizes prostaglandin F2α (PGF2α) analogs with a neutral substituent at position 1 [abstract]. Invest Ophthalmol Vis Sci 40:S675, 1999
11. Laibovitz RA, VanDenburgh AM, Felix C, et al: Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol (in press)
12. Maihöfner C, Schloetzer-Schrehardt U, Gühring H, et al.  Expression of cyclooxygenase-2 in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 1999;40:S827;[abstract]
13. Michels-Rautenstrauss K, Mardin CY, Schweitzer D, et al.  GLCIA-locus (mutation screening in MYOC/TIGR and COX-2 of German POAG patients). Proc Am Soc Human Genetics. 2000;65:2731;[abstract]
14. Resul B, Stjernschantz J, Selen G, Bito L: Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41 (Suppl 2) S47–52, 1997
15. Toris CB, Camras CB, Yablonski ME. Effect of PhXA41, a new prostaglandin PGF2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
    • Abstract
16. Woodward DF, Krauss AH-P, Chen J. Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000;130:1933–1943
    • MEDLINE
    • CrossRef
17. Woodward DF, Tang-Liu DD-S, Madhu C, et al: Prostaglandin F2α (PGF2α) 1-ethanolamide: a pharmacologically unique local hormone biosynthesized from anandamide. 11th International Conference on Advances in Prostaglandin and Leukotriene Research 2000, p 27
18. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272:21181–21186
    • MEDLINE
    • CrossRef